RISPERDAL

RISPERDAL

Risperdal is an anti-psychotic medication approved to treat symptoms of schizophrenia, bipolar disorder, and autism. Unfortunately, doctors have also prescribed Risperdal for unapproved uses, and some users have experienced serious and unexpected side effects. In addition to other serious side effects, the use of Risperdal has been linked to a condition called gynecomastia, or the growth of female breasts on boys. The tissue is not cancerous, but it can be painful and embarrassing, especially for teenage males. For this reason, many doctors recommend surgery. Severe gynecomastia may require a surgical procedure called a mastectomy, which involves the removal of breast tissue and excess skin. Gynecomastia has been especially devastating for young boys who have taken the drug.

The U.S. Food & Drug Administration (FDA) has issued several warnings related to the drug, emphasizing the dangers it may pose to users. And in 2006, the Journal of Clinical Psychopharmacology noted that Risperdal administered to adolescents at doses commonly used for the treatment of psychotic symptoms can strongly increase prolactin levels, with clinical consequences such as gynecomastiarisperidone should be administered with caution to children and adolescents.”

Other studies have found that young men on Risperdal may be 5-times as likely to develop gynecomastia. The risk also increases for older men, who may be 69% more likely to develop gynecomastia compared to men who do not take antipsychotic drugs.

The Gabrielli Firm is currently accepting Risperdal induced injury cases in all 50 states. If you or your son was diagnosed with gynecomastia, you should contact our lawyers immediately for a free case consultation.

HERNIA MESH

HERNIA MESH

Hernias have a high risk of re-opening (called “recurrence“). To reduce this risk, most surgeons stitch in a mesh patch or plug to help reinforce muscles and connective tissues. They can be synthetic or non-synthetic, permanent or absorbable. Some patches work better than others. For example, Physiomesh was withdrawn from the market due to higher rates of recurrence.

Manufacturers of hernia mesh are in the midst of lawsuits regarding complications arising from the use of mesh in hernia medical procedures. Complications include chronic pain, infections or abscesses, hernia recurrence, scar-like tissue that sticks tissues together (adhesion), blockage of the large or small intestine, organ perforation, mesh migration or erosion, mesh shrinkage (contraction) or the need for another surgery.

Johnson & Johnson, manufacturer of Ethicon Physiomesh Flexible Composite, and Atrium, manufacturer of C-Qur Mesh, are included in a host of new lawsuits alleging defective, dangerous design.

The Gabrielli Firm is currently accepting hernia mesh induced injury cases in all 50 states. If you or somebody you know was injured by Ethicon Physiomesh or C-Qur Mesh, you should contact our lawyers immediately for a free case consultation.

BREAST IMPLANTS

BREAST IMPLANTS

The FDA has identified an association between breast implants and the development of anaplastic large cell lymphoma (ALCL), a rare type of non-Hodgkin’s lymphoma. This rare cancer affects cells in the immune system and can be found around the breast implant. It can be found in the skin or lymph nodes, and is not a type of breast cancer.

As of 1 February 2017, the FDA says it has received a total of 359 reports of breast implants and the development of ALCL, including nine deaths.

Most of these cancer cases occurred in people who had textured surfaces on their implants, rather than smooth surfaces.

The Gabrielli Law Firm is investigating cases on behalf of women who have developed ALCL after having breast implants. We offer a free, confidential consultation to discuss your concerns as well as how we can help.

TAXOTERE

TAXOTERE

Taxotere (Docetaxel) is a chemotherapy drug manufactured and marketed by Sanofi-Aventis. Doctors prescribe the drug to treat the majority of breast cancer cases in the U.S. The treatment plan for Taxotere is once every three weeks, unlike Paclitaxel, a drug in the same class, which is weekly and just as effective.

The Taxotere lawsuit states that Sanofi-Aventis failed to warn patients and physicians of the increased risks of permanent alopecia (loss of hair) through the use of Taxotere during chemotherapy. Sanofi-Aventis warned other countries about alopecia risk but did not warn women in the U.S. If properly warned of the risks associated with Taxotere, patients would have been prescribed a different chemotherapy drug that did not result in permanent hair loss.

The Gabrielli Firm is currently accepting Taxotere cases in all 50 states. If you or somebody you know was injured by Taxotere, you should contact our lawyers immediately for a free case consultation.